Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11961352 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL1487007 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL765807 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL8520973 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL345859 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL11961353 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL366852 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL3974543 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL16730247 | 0.84 | CA2 (0.32) | CA2 | |
| SCHEMBL3016063 | 0.84 | CA2 (0.32) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3255043-B1 | N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2021-01-20 | — | — | EP | disclosed |
| EP-3255043-B1 | N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2021-01-20 | — | — | EP | disclosed |
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | ARDEA BIOSCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200281878-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2020-09-10 | — | — | US | disclosed |
| WO-2019055509-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20180221312-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180221312-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-9975881-B2 | Compound | ASTRAZENECA AB (SE) | 2018-05-22 | — | — | US | disclosed |
| US-9975881-B2 | Compound | ASTRAZENECA AB (SE) | 2018-05-22 | — | — | US | disclosed |
| US-9975881-B2 | Compound | ASTRAZENECA AB (SE) | 2018-05-22 | — | — | US | disclosed |
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| EP-2311827-A1 | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators. | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2301933-A1 | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-7838675-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2010-11-23 | — | — | US | disclosed |
| WO-2010084300-A2 | STEM CELL CULTURE METHODS | ITI SCOTLAND LIMITED (GB) | 2010-07-29 | — | — | WO | disclosed |
| US-7417064-B2 | 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ELI LILLY AND COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7410982-B2 | Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410996-B2 | 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| CN-101048401-A | Pyrimidine sulfonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2007-10-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221312-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | CXCR1, CXCR2, CXCR6 | L3MBTL1 4328/4885CA2 1735/4885 |
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | CXCR1, CXCR2, CXCR6 | L3MBTL1 3158/4885CA2 1857/4885 |
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | L3MBTL1 4559/4885CA2 3334/4885 |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | L3MBTL1 4496/4885CA2 3317/4885 |
| US-20200281878-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | CXCR1, CXCR2, CXCR6 | L3MBTL1 4328/4885CA2 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.